ETHIOPIAN PUBLIC HEALTH INSTITUTE
           REFERENCE MANAGEMENT SYSTEM
Subscribe to RSS feed
                                

WIKINDX Resources

Mesfin, E. A., Beyene, D., Tesfaye, A., Admasu, A., Addise, D., & Amare, M., et al. (2018). Drug-resistance patterns of mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from ethiopia. PLoS ONE, 13(6), e0197737. 
Resource type: Journal Article
DOI: 10.1371/journal.pone.0197737
ID no. (ISBN etc.): 1932-6203
BibTeX citation key: Mesfin2018
View all bibliographic details
Categories: General
Keywords: drug therapy, Ethiopia, Extensively drug-resistant tuberculosis, Health care facilities, Medical risk factors, Multi-drug-resistant tuberculosis, Mycobacterium tuberculosis, Tuberculosis
Creators: Addise, Admasu, Amare, Beyene, Dagne, Mesfin, Tesfaye, Tesfaye, Tessema, Yaregal
Collection: PLoS ONE
Attachments   URLs   https://dx.plos.or ... urnal.pone.0197737
Abstract
{Background Multidrug drug-resistant tuberculosis (MDR-TB) is a major health problem and seriously threatens TB control and prevention efforts globally. Ethiopia is among the 30th highest TB burden countries for MDR-TB with 14% prevalence among previously treated cases. The focus of this study was on determining drug resistance patterns of Mycobacterium tuberculosis among MDR-TB suspected cases and associated risk factors. Methods A cross-sectional study was conducted in Addis Ababa from June 2015 to December 2016. Sputum samples and socio-demographic data were collected from 358 MDR-TB suspected cases. Samples were analyzed using Ziehl-Neelsen technique, GeneXpert MTB/RIF assay, and culture using Lowenstein-Jensen and Mycobacterial growth indicator tube. Data were analyzed using SPSS version 23. Results A total of 226 the study participants were culture positive for Mycobacterium tuberculosis, among them, 133 (58.8%) participants were males. Moreover, 162 (71.7%) had been previously treated for tuberculosis, while 128 (56.6%) were TB/HIV co-infected. A majority [122 (54%)] of the isolates were resistant to any first-line anti-TB drugs. Among the resistant isolates, 110 (48.7%) were determined to be resistant to isoniazid, 94 (41.6%) to streptomycin, 89 (39.4%) to rifampicin, 72 (31.9%) to ethambutol, and 70 (30.9%) to pyrazinamide. The prevalence of MDR-TB was 89 (39.4%), of which 52/89 (58.4%) isolates were resistance to all five first-line drugs. Risk factors such as TB/HIV co-infection (AOR = 5.59